Compare UNP & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNP | NVO |
|---|---|---|
| Founded | 1862 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.9B | 199.4B |
| IPO Year | 2005 | 2001 |
| Metric | UNP | NVO |
|---|---|---|
| Price | $307.16 | $40.51 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 25 | 14 |
| Target Price | ★ $331.38 | $45.03 |
| AVG Volume (30 Days) | 2.2M | ★ 8.5M |
| Earning Date | 10-22-2026 | 11-04-2026 |
| Dividend Yield | 1.87% | ★ 3.20% |
| EPS Growth | ★ 8.03 | N/A |
| EPS | ★ 9.71 | N/A |
| Revenue | ★ $19,533,000,000.00 | N/A |
| Revenue This Year | $11.74 | N/A |
| Revenue Next Year | $5.75 | $1.35 |
| P/E Ratio | $31.20 | ★ $13.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $216.32 | $35.12 |
| 52 Week High | $315.99 | $64.16 |
| Indicator | UNP | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 72.61 | 57.16 |
| Support Level | $281.69 | $35.49 |
| Resistance Level | $315.07 | $41.41 |
| Average True Range (ATR) | 6.03 | 0.58 |
| MACD | 2.07 | 0.37 |
| Stochastic Oscillator | 98.23 | 93.58 |
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two-thirds of the US, Union Pacific generated $24.5 billion of revenue in 2025 by hauling coal, industrial products, intermodal containers, agricultural goods, chemicals, fertilizers, and automotive goods. Union Pacific owns about one-fourth of Mexican railroad Ferromex and historically derives roughly 10% of its revenue hauling freight to and from Mexico.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.